Imaging the aging brain: study design and baseline findings of the SENIOR cohort.


Journal

Alzheimer's research & therapy
ISSN: 1758-9193
Titre abrégé: Alzheimers Res Ther
Pays: England
ID NLM: 101511643

Informations de publication

Date de publication:
26 06 2020
Historique:
received: 14 10 2019
accepted: 11 06 2020
entrez: 28 6 2020
pubmed: 28 6 2020
medline: 25 6 2021
Statut: epublish

Résumé

Current demographic trends point towards an aging society entailing increasing occurrence and burden of neurodegenerative diseases. In this context, understanding physiological aging and its turning point into neurodegeneration is essential for the development of possible biomarkers and future therapeutics of brain disease. The SENIOR study represents a longitudinal, observational study including cognitively healthy elderlies aged between 50 and 70 years old at the time of inclusion, being followed annually over 10 years. Our multimodal protocol includes structural, diffusion, functional, and sodium magnetic resonance imaging (MRI) at 3 T and 7 T, positron emission tomography (PET), blood samples, genetics, audiometry, and neuropsychological and neurological examinations as well as assessment of neuronal risk factors. One hundred forty-two participants (50% females) were enrolled in the SENIOR cohort with a mean age of 60 (SD 6.3) years at baseline. Baseline results with multiple regression analyses reveal that cerebral white matter lesions can be predicted by cardiovascular and cognitive risk factors and age. Cardiovascular risk factors were strongly associated with juxtacortical and periventricular lesions. Intra-subject across-test variability as a measure of neuropsychological test performance and possible cognitive marker predicts white matter volume and is significantly associated with risk profile. Division of the cohort into subjects with a higher and lower risk profile shows significant differences in intra-subject across-test variability and volumes as well as cortical thickness of brain regions of the temporal lobe. There is no difference between the lower- and higher-risk groups in amyloid load using PET data from a subset of 81 subjects. We here describe the study protocol and baseline findings of the SENIOR observational study which aim is the establishment of integrated, multiparametric maps of normal aging and the identification of early biomarkers for neurodegeneration. We show that intra-subject across-test variability as a marker of neuropsychological test performance as well as age, gender, and combined risk factors influence neuronal decline as represented by decrease in brain volume, cortical thickness, and increase in white matter lesions. Baseline findings will be used as underlying basis for the further implications of aging and neuronal degeneration as well as examination of brain aging under different aspects of brain pathology versus physiological aging.

Sections du résumé

BACKGROUND
Current demographic trends point towards an aging society entailing increasing occurrence and burden of neurodegenerative diseases. In this context, understanding physiological aging and its turning point into neurodegeneration is essential for the development of possible biomarkers and future therapeutics of brain disease.
METHODS
The SENIOR study represents a longitudinal, observational study including cognitively healthy elderlies aged between 50 and 70 years old at the time of inclusion, being followed annually over 10 years. Our multimodal protocol includes structural, diffusion, functional, and sodium magnetic resonance imaging (MRI) at 3 T and 7 T, positron emission tomography (PET), blood samples, genetics, audiometry, and neuropsychological and neurological examinations as well as assessment of neuronal risk factors.
RESULTS
One hundred forty-two participants (50% females) were enrolled in the SENIOR cohort with a mean age of 60 (SD 6.3) years at baseline. Baseline results with multiple regression analyses reveal that cerebral white matter lesions can be predicted by cardiovascular and cognitive risk factors and age. Cardiovascular risk factors were strongly associated with juxtacortical and periventricular lesions. Intra-subject across-test variability as a measure of neuropsychological test performance and possible cognitive marker predicts white matter volume and is significantly associated with risk profile. Division of the cohort into subjects with a higher and lower risk profile shows significant differences in intra-subject across-test variability and volumes as well as cortical thickness of brain regions of the temporal lobe. There is no difference between the lower- and higher-risk groups in amyloid load using PET data from a subset of 81 subjects.
CONCLUSIONS
We here describe the study protocol and baseline findings of the SENIOR observational study which aim is the establishment of integrated, multiparametric maps of normal aging and the identification of early biomarkers for neurodegeneration. We show that intra-subject across-test variability as a marker of neuropsychological test performance as well as age, gender, and combined risk factors influence neuronal decline as represented by decrease in brain volume, cortical thickness, and increase in white matter lesions. Baseline findings will be used as underlying basis for the further implications of aging and neuronal degeneration as well as examination of brain aging under different aspects of brain pathology versus physiological aging.

Identifiants

pubmed: 32591008
doi: 10.1186/s13195-020-00642-1
pii: 10.1186/s13195-020-00642-1
pmc: PMC7320588
doi:

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

77

Investigateurs

Christine Baron (C)
Valérie Berland (V)
Nathalie Blancho (N)
Séverine Desmidt (S)
Christine Doublé (C)
Chantal Ginisty (C)
Véronique Joly-Testault (V)
Laurence Laurier (L)
Yann Lecomte (Y)
Claire Leroy (C)
Christine Manciot (C)
Stephanie Marchand (S)
Gaelle Mediouni (G)
Xavier Millot (X)
Ludivine Monassier (L)
Séverine Roger (S)
Catherine Vuillemard (C)

Références

J Int Neuropsychol Soc. 2003 Sep;9(6):864-70
pubmed: 14632245
J Neurol Neurosurg Psychiatry. 2005 Dec;76 Suppl 5:v2-7
pubmed: 16291918
Neuroimage Clin. 2014 Jul 31;5:341-8
pubmed: 25161900
Brain. 2005 May;128(Pt 5):1093-101
pubmed: 15774508
Science. 2002 Jul 19;297(5580):353-6
pubmed: 12130773
Neurobiol Aging. 2000 Mar-Apr;21(2):153-60
pubmed: 10867200
Lancet Neurol. 2010 Nov;9(11):1118-27
pubmed: 20934914
Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):11050-5
pubmed: 10984517
World Health Organ Tech Rep Ser. 2000;894:i-xii, 1-253
pubmed: 11234459
Neuroimage Clin. 2013 Mar 05;2:356-65
pubmed: 24179789
Neurology. 2019 Oct 22;93(17):e1647-e1659
pubmed: 31371569
Stroke. 2004 Aug;35(8):1857-61
pubmed: 15218158
Brain. 2016 Apr;139(Pt 4):1252-64
pubmed: 26984188
Brain. 2011 Jul;134(Pt 7):2036-43
pubmed: 21705422
Magn Reson Imaging. 2019 May;58:116-124
pubmed: 30695720
Neurology. 2012 Jan 24;78(4):232-40
pubmed: 22189452
Lancet Neurol. 2019 Jan;18(1):88-106
pubmed: 30497964
Ann Neurol. 2010 Mar;67(3):353-64
pubmed: 20373347
IEEE Trans Med Imaging. 1998 Feb;17(1):87-97
pubmed: 9617910
J Neurosci. 2003 Apr 15;23(8):3295-301
pubmed: 12716936
Am J Geriatr Psychiatry. 2014 Nov;22(11):1200-9
pubmed: 23831178
Lancet Neurol. 2008 Aug;7(8):704-14
pubmed: 18635019
JAMA Neurol. 2017 Oct 1;74(10):1178-1189
pubmed: 28846757
Nat Rev Neurol. 2013 Feb;9(2):106-18
pubmed: 23296339
Magn Reson Med. 2002 Oct;48(4):577-82
pubmed: 12353272
J Neurol Neurosurg Psychiatry. 2004 Sep;75(9):1304-8
pubmed: 15314121
J Nucl Med. 2008 Jun;49(6):1000-8
pubmed: 18511844
Adv Neurobiol. 2017;15:491-528
pubmed: 28674995
Exp Clin Cardiol. 2008 Summer;13(2):71-4
pubmed: 19343119
Neurol Ther. 2017 Jul;6(Suppl 1):5-13
pubmed: 28733961
Lancet. 2017 Dec 16;390(10113):2673-2734
pubmed: 28735855
Nat Protoc. 2006;1(2):892-9
pubmed: 17406322
Maturitas. 2014 Oct;79(2):184-90
pubmed: 24931304
Lancet Neurol. 2014 Aug;13(8):788-94
pubmed: 25030513
Cereb Cortex. 2004 Jan;14(1):11-22
pubmed: 14654453
Neurology. 2014 May 20;82(20):1760-7
pubmed: 24748674
J Psychiatr Res. 1982-1983;17(1):37-49
pubmed: 7183759
Neurology. 2006 Aug 8;67(3):446-52
pubmed: 16894106
J Int Neuropsychol Soc. 2016 Nov;22(10):1016-1025
pubmed: 27903330
Ann Hum Genet. 1999 Jul;63(Pt 4):301-10
pubmed: 10738542
Brain. 2009 May;132(Pt 5):1355-65
pubmed: 19339253
JAMA. 2008 Aug 20;300(7):823-30
pubmed: 18714062
J Neuropathol Exp Neurol. 2016 Apr;75(4):316-25
pubmed: 26979082
Lancet Neurol. 2010 Jan;9(1):119-28
pubmed: 20083042
Neurology. 2014 Aug 19;83(8):702-9
pubmed: 25080520
Sci Rep. 2019 Feb 13;9(1):1952
pubmed: 30760848
Magn Reson Med. 1997 Mar;37(3):470-7
pubmed: 9055238
Ann Hum Biol. 2006 May-Jun;33(3):279-308
pubmed: 17092867
Stat Med. 2001 Dec 30;20(24):3695-714
pubmed: 11782027
Prog Nucl Magn Reson Spectrosc. 2014 May;79:14-47
pubmed: 24815363
BMC Public Health. 2014 Jun 24;14:643
pubmed: 24962204
Neurology. 2019 Mar 5;92(10):e1041-e1050
pubmed: 30728309
Int J Cardiol Heart Vasc. 2018 May 14;19:63-69
pubmed: 29946567
Curr Gerontol Geriatr Res. 2013;2013:495793
pubmed: 24454359
Alzheimer Dis Assoc Disord. 2011 Oct-Dec;25(4):289-304
pubmed: 21750453
Neuroimage. 2010 Dec;53(4):1181-96
pubmed: 20637289
Neuroimage. 2012 Oct 15;63(1):517-24
pubmed: 22796981
Int J Geriatr Psychiatry. 2011 Oct;26(10):991-9
pubmed: 21905095
Nature. 2016 Nov 09;539(7628):180-186
pubmed: 27830812
Neurology. 2004 Apr 27;62(8):1317-22
pubmed: 15111668
Nature. 2011 Aug 31;477(7362):90-4
pubmed: 21886162
Neurology. 2015 Aug 11;85(6):535-42
pubmed: 26180144
Neurology. 2006 Nov 14;67(9):1575-80
pubmed: 16971697
Neuron. 2002 Jan 31;33(3):341-55
pubmed: 11832223
Postgrad Med J. 2006 Feb;82(964):84-8
pubmed: 16461469
Front Neuroinform. 2016 Jul 27;10:30
pubmed: 27512372
Arch Gen Psychiatry. 2012 May;69(5):499-505
pubmed: 22566582
Neurosci Biobehav Rev. 2013 Dec;37(10 Pt 2):2878-86
pubmed: 24183852
JAMA Netw Open. 2019 Jul 3;2(7):e198112
pubmed: 31365110
Front Aging Neurosci. 2014 Jul 04;6:147
pubmed: 25071556
Neuroimage. 2004 Jul;22(3):1060-75
pubmed: 15219578

Auteurs

Alexa Haeger (A)

NeuroSpin, Frédéric Joliot Life Sciences Institute, CEA, Paris-Saclay University, Gif-sur-Yvette, France.
Department of Neurology, RWTH Aachen University, Aachen, Germany.
JARA-BRAIN Institute Molecular Neuroscience and Neuroimaging, Forschungszentrum Jülich GmbH and RWTH Aachen University, Aachen, Germany.

Jean-François Mangin (JF)

NeuroSpin, Frédéric Joliot Life Sciences Institute, CEA, Paris-Saclay University, Gif-sur-Yvette, France.

Alexandre Vignaud (A)

NeuroSpin, Frédéric Joliot Life Sciences Institute, CEA, Paris-Saclay University, Gif-sur-Yvette, France.

Cyril Poupon (C)

NeuroSpin, Frédéric Joliot Life Sciences Institute, CEA, Paris-Saclay University, Gif-sur-Yvette, France.

Antoine Grigis (A)

NeuroSpin, Frédéric Joliot Life Sciences Institute, CEA, Paris-Saclay University, Gif-sur-Yvette, France.

Fawzi Boumezbeur (F)

NeuroSpin, Frédéric Joliot Life Sciences Institute, CEA, Paris-Saclay University, Gif-sur-Yvette, France.

Vincent Frouin (V)

NeuroSpin, Frédéric Joliot Life Sciences Institute, CEA, Paris-Saclay University, Gif-sur-Yvette, France.

Jean-Robert Deverre (JR)

NeuroSpin, Frédéric Joliot Life Sciences Institute, CEA, Paris-Saclay University, Gif-sur-Yvette, France.

Marie Sarazin (M)

Unit of Neurology of Memory and Language, GHU Paris Psychiatry and Neurosciences, Paris University, Paris, France.
Paris-Saclay University, CEA, CNRS, INSERM, BioMaps, Service Hospitalier Frédéric Joliot, F-91400, Orsay, France.

Lucie Hertz-Pannier (L)

NeuroSpin, Frédéric Joliot Life Sciences Institute, CEA, Paris-Saclay University, Gif-sur-Yvette, France.

Michel Bottlaender (M)

NeuroSpin, Frédéric Joliot Life Sciences Institute, CEA, Paris-Saclay University, Gif-sur-Yvette, France. michel.bottlaender@cea.fr.
Paris-Saclay University, CEA, CNRS, INSERM, BioMaps, Service Hospitalier Frédéric Joliot, F-91400, Orsay, France. michel.bottlaender@cea.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH